Boundless Bio, Debt To Equity vs. EBITDA

BOLD Stock  USD 2.73  0.21  8.33%   
Based on the key profitability measurements obtained from Boundless Bio,'s financial statements, Boundless Bio, Common may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Boundless Bio,'s ability to earn profits and add value for shareholders.
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.0184
Current Value
0.0311
Quarterly Volatility
0.00779862
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Boundless Bio,'s ROE is projected to increase slightly based on the last few years of reporting. The current year's EV To Operating Cash Flow is expected to grow to 0.48, whereas Book Value Per Share is projected to grow to (5.43).
For Boundless Bio, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Boundless Bio, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Boundless Bio, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Boundless Bio,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Boundless Bio, Common over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.59)
Return On Assets
(0.24)
Return On Equity
(0.36)
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Boundless Bio, Common EBITDA vs. Debt To Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Boundless Bio,'s current stock value. Our valuation model uses many indicators to compare Boundless Bio, value to that of its competitors to determine the firm's financial worth.
Boundless Bio, Common is number one stock in debt to equity category among its peers. It also is number one stock in ebitda category among its peers . At present, Boundless Bio,'s Debt To Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Boundless Bio, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Boundless EBITDA vs. Debt To Equity

Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Boundless Bio,

D/E

 = 

Total Debt

Total Equity

 = 
0.08 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Boundless Bio,

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(48.48 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Boundless EBITDA Comparison

Boundless Bio, is currently under evaluation in ebitda category among its peers.

Boundless Bio, Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Boundless Bio,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Boundless Bio, will eventually generate negative long term returns. The profitability progress is the general direction of Boundless Bio,'s change in net profit over the period of time. It can combine multiple indicators of Boundless Bio,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income40 K42 K
Operating Income-54.8 M-57.5 M
Income Before Tax-49.4 M-51.9 M
Total Other Income Expense Net5.4 M5.6 M
Net Loss-49.4 M-51.9 M
Income Tax Expense-5.3 M-5 M
Net Interest Income5.3 M5.5 M
Interest Income5.3 M5.5 M
Net Loss-49.4 M-51.9 M
Net Loss(2.22)(2.33)
Income Quality 0.95  0.71 
Net Income Per E B T 0.88  0.78 

Boundless Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Boundless Bio,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Boundless Bio, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Boundless Bio,'s important profitability drivers and their relationship over time.

Use Boundless Bio, in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Boundless Bio, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Boundless Bio, will appreciate offsetting losses from the drop in the long position's value.

Boundless Bio, Pair Trading

Boundless Bio, Common Pair Trading Analysis

The ability to find closely correlated positions to Boundless Bio, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Boundless Bio, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Boundless Bio, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Boundless Bio, Common to buy it.
The correlation of Boundless Bio, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Boundless Bio, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Boundless Bio, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Boundless Bio, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Boundless Bio, position

In addition to having Boundless Bio, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Beer and Liquor Thematic Idea Now

Beer and Liquor
Beer and Liquor Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Beer and Liquor theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beer and Liquor Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:
Check out Trending Equities.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
To fully project Boundless Bio,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Boundless Bio, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Boundless Bio,'s income statement, its balance sheet, and the statement of cash flows.
Potential Boundless Bio, investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Boundless Bio, investors may work on each financial statement separately, they are all related. The changes in Boundless Bio,'s assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Boundless Bio,'s income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.